Hyperchol Mechanism of Action

Fenofibrate can reduce blood cholesterol levels up to 20-25% and blood triglyceride levels up to 40-50%.
It produces reductions in the low density atherogenic fractions of cholesterol (VLDL and LDL), thus improving cholesterol distribution in plasma. Fenofibrate reduces the total cholesterol/HDL cholesterol ratio, this ratio increases during atherogenic hyperlipidemia conditions.
The rapid increase of LDL in liver cells is a result of the inhibition of HMG-CoA reductase, a condition that can be improved by Fenofibrate.
Fenofibrate increases apolipoprotein A1 levels and reduces apolipoprotein B levels, thereby improving the apo A1/apo B ratio, the indicator for atherogenic risk.
Extravascular cholesterol reserves (xanthum tendinosum and tuberosum) can experience significant regression or can disappear completely on prolonged effective usage of the drug.
Increased urinary excretion of uric acid, which plays an important role in reducing mean blood uric acid levels up to 25% has been observed in hyperlipidemic patients.
An antiaggregation effect has been observed in clinical studies. It was the result of reduction of aggregation related to ADP, arachidonic acid and epinephrine.